A Phase I Study of Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

Trial Profile

A Phase I Study of Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs Avelumab (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary) ; Utomilumab (Primary) ; Carboplatin; Etoposide phosphate; Ifosfamide
  • Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jun 2018 Planned End Date changed from 16 Jun 2020 to 8 Jun 2020.
    • 13 Jun 2018 Planned primary completion date changed from 16 Jun 2020 to 8 Jun 2020.
    • 18 Apr 2018 Planned number of patients changed from 30 to 39.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top